Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases

Author(s): Paulo Gustavo Kotze , Laurent Peyrin-Biroulet , Silvio Danese .

Journal Name: Current Drug Targets

Volume 20 , Issue 13 , 2019

Become EABM
Become Reviewer

[1]
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017; 6736(17): 1-10.
[2]
Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO Guideline / Consensus Paper ECCO-ESCP Consensus on Surgery for Crohn ’ s Disease. J Crohn’s Colitis 2018; 12(1): 1-16.
[3]
Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63(10): 1607-16.
[4]
Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol 2017; 33(4): 246-53.
[5]
Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol 2016; 1(4): 307-16.
[6]
Bemelman WA. Evolving role of IBD surgery. J Crohn’s Colitis 2018; 12(8): 1005-7.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 13
Year: 2019
Page: [1315 - 1316]
Pages: 2
DOI: 10.2174/138945012013190902150906

Article Metrics

PDF: 13
HTML: 1
EPUB: 1
PRC: 1